Printer Friendly

SONUS PHARMACEUTICALS AND ABBOTT LABORATORIES SIGN MANUFACTURING AGREEMENT

 COSTA MESA, Calif., July 13 /PRNewswire/ -- Sonus Pharmaceuticals Inc. has signed an agreement with Abbott Laboratories for the manufacture of its first product line, EchoGen(TM) ultrasound contrast agents for echocardiology and general radiology.
 The agreement calls for a cooperative pharmaceutical development process during clinical trials and a manufacture and supply arrangement following Food and Drug Administration approval. Other details of the contract were not disclosed.
 "This agreement represents a significant step in the growth of Sonus and signals its passage from a purely research-intensive organization to a development-stage company," said Steven C. Quay, M.D., Ph.D., Sonus founder, chairman and chief executive officer. "The ability to attract the interest and commitment of an excellent pharmaceutical company in Abbott Laboratories is important, since our rapid product development requires that we execute the manufacturing scale-up, clinical-trial supplies, and product stability studies correctly the first time. Working with Abbott gives me the confidence this can be achieved within our aggressive time table."
 "We are pleased to be able to work with Sonus in this critical phase of their product development," said John G. Kringle, senior vice president, Hospital Products Division, Abbott Laboratories.
 Abbott Laboratories is a worldwide manufacturer of health care products, employing 48,000 people. In 1992, the company's sales and net earnings were $7.9 billion and $1.2 billion, respectively, with earnings per share of $1.47.
 Sonus Pharmaceuticals Inc. of Costa Mesa, a private company, was founded in 1991 to develop and commercialize novel ultrasound contrast agents for diagnostic applications in echocardiology, general radiology, gynecology and neuroradiology using the company's proprietary PhaseShift(TM) and High Q-Factor(TM) Gas Technologies.
 -0- 7/13/93
 /CONTACT: Tom Gable or Kris Lichter of Gable/Versaggi Biocommunications, 619-234-1300, for Sonus Pharmaceuticals/


CO: Sonus Pharmaceuticals Inc.; Abbott Laboratories ST: California IN: MTC SU: CON

LS-MF -- SD001 -- 0730 07/13/93 08:32 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 13, 1993
Words:311
Previous Article:GE SECOND QUARTER NET EARNINGS PER SHARE UP 10 PERCENT TO $1.56
Next Article:CHARTER GOLF ANNOUNCES PLANS TO EXPAND INTO HAT BUSINESS; SALES CONTINUE VERY STRONG
Topics:


Related Articles
SONUS PHARMACEUTICALS NAMES DENNIS FOWLER, M.D., Ph.D., VICE PRESIDENT, CLINICAL DEVELOPMENT
SONUS PHARMACEUTICALS AND ABBOTT LABORATORIES SIGN AGREEMENT FOR ECHOGEN(R) EMULSION IN THE U.S.
/C O R R E C T I O N -- SONUS PHARMACEUTICALS, INC./(Correction Notice)
Abbott and North American Vaccine Form Marketing Alliance
SONUS Pharmaceuticals Announces Third Quarter Results
Premier Announces Abbott Laboratories As New Corporate Partner
Abbott Announces Long-Term Agreement With Consorta.
SONUS Pharmaceuticals and Abbott Laboratories Discuss Changes In EchoGen Marketing and Distribution Responsibilities.
Abbott Announces Multi-Year Agreement With Consorta.
Abbott Announces Five-Year Agreement with Consorta.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters